ESR1 and neoplasm: The PD-L1 expression is assumed to be 20–40% and 40–60% for ER+ and TNBC, respectively, estimated based on human data [43]; the tumour growth rate of each subtype is estimated using the mean tumour doubling time and standard deviation from clinical measurements [44].